PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32909438-6 2021 The most common reasons for ordering serum albumin levels in intensive care unit (ICU) settings are to guide albumin administration, to estimate free phenytoin or calcium levels, for nutritional monitoring, and for severity-of-illness assessment. Phenytoin 150-159 albumin Homo sapiens 43-50 16918714-0 2006 Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Phenytoin 92-101 albumin Homo sapiens 16-29 25211555-4 2014 The binding kinetics of human serum albumin (HSA) to tolbutamide and to phenytoin are in quantitative agreement with previous measurements, and our single-molecule approach reveals a biexponential behavior characteristic of a multistep process. Phenytoin 72-81 albumin Homo sapiens 30-43 23670246-0 2014 The quantitative effect of serum albumin, serum urea, and valproic acid on unbound phenytoin concentrations in children. Phenytoin 83-92 albumin Homo sapiens 27-40 23670246-6 2014 Serum albumin, serum urea concentrations, and concomitant valproic acid use significantly influenced the unbound phenytoin fraction. Phenytoin 113-122 albumin Homo sapiens 0-13 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 194-201 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 235-242 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 342-349 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 194-201 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 235-242 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 342-349 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 194-201 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 235-242 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 342-349 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 194-201 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 235-242 26825643-1 2016 OBJECTIVE: In settings where free phenytoin concentrations are not available, the Sheiner-Tozer equation-Corrected total phenytoin concentration = Observed total phenytoin concentration/[(0.2 x Albumin) + 0.1]; phenytoin in microg/mL, albumin in g/dL-and its derivative equations are commonly used to correct for altered phenytoin binding to albumin. Phenytoin 121-130 albumin Homo sapiens 342-349 18256202-1 2008 This study characterized the mechanism by which bovine serum albumin (BSA) reduces the K(m) for phenytoin (PHY) hydroxylation and the implications of the "albumin effect" for in vitro-in vivo extrapolation of kinetic data for CYP2C9 substrates. Phenytoin 96-105 albumin Homo sapiens 55-68 2244404-0 1990 Correlation of free phenytoin to serum albumin in cancer patients. Phenytoin 20-29 albumin Homo sapiens 39-46 17073425-2 2006 This approach was evaluated by using it to determine the free fraction of phenytoin in serum or samples containing the binding protein human serum albumin (HSA). Phenytoin 74-83 albumin Homo sapiens 141-154 16621742-0 2006 Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin. Phenytoin 55-64 albumin Homo sapiens 86-99 16621742-1 2006 Biointeraction studies based on high performance affinity chromatography were used to investigate the binding of human serum albumin (HSA) to two major phenytoin metabolites: 5-(3-hydroxyphenyl)-5-phenylhydantoin (m-HPPH) and 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Phenytoin 152-161 albumin Homo sapiens 119-132 15516024-14 2004 CONCLUSION: In patients with serum albumin levels in the hyper- and hypoalbuminemic range, corrected phenytoin levels were better indicators of clinical outcome. Phenytoin 101-110 albumin Homo sapiens 29-42 11930452-3 2000 The effect of phenytoin within the body is dependent on the amount of serum albumin and the functional status of the major organs in the body. Phenytoin 14-23 albumin Homo sapiens 76-83 11930452-5 2000 Closer investigation of total serum phenytoin and serum albumin ratio by primary care providers is necessary for monitoring therapeutic levels of phenytoin therapy. Phenytoin 146-155 albumin Homo sapiens 56-63 1823294-0 1991 [Binding of phenytoin to serum albumin in vitro and in vivo]. Phenytoin 12-21 albumin Homo sapiens 31-38 1823294-1 1991 The present paper describes an ultrafiltration method of determination of the concentration of free phenytoin (DPH) in serum and its use for the study of the binding equilibrium phenytoin--albumin. Phenytoin 100-109 albumin Homo sapiens 189-196 1823294-1 1991 The present paper describes an ultrafiltration method of determination of the concentration of free phenytoin (DPH) in serum and its use for the study of the binding equilibrium phenytoin--albumin. Phenytoin 111-114 albumin Homo sapiens 189-196 15516024-0 2004 Serum albumin-adjusted phenytoin levels: an approach for predicting drug efficacy in patients with epilepsy, suitable for developing countries. Phenytoin 23-32 albumin Homo sapiens 0-13 15516024-3 2004 This study was designed to investigate whether serum albumin-adjusted phenytoin levels in Indian patients with epilepsy predict clinical outcome better than total phenytoin levels. Phenytoin 70-79 albumin Homo sapiens 47-60 15282104-0 2004 Studies of phenytoin binding to human serum albumin by high-performance affinity chromatography. Phenytoin 11-20 albumin Homo sapiens 38-51 15282104-1 2004 High-performance affinity chromatography was used to study the binding of phenytoin to an immobilized human serum albumin (HSA) column. Phenytoin 74-83 albumin Homo sapiens 108-121 11466022-1 2001 Our objective was to investigate the relationship between phenytoin bioavailability, enteral feeding and serum albumin levels in patients admitted to neurology/neurosurgery ITU, via case studies of three patients. Phenytoin 58-67 albumin Homo sapiens 111-118 11466022-3 2001 Phenytoin levels were assessed in relation to the type of feeding and serum albumin levels. Phenytoin 0-9 albumin Homo sapiens 76-83 11466022-4 2001 We found evidence of a complex relationship between phenytoin levels, enteral feeding and serum albumin in patients in the neuro ITU setting. Phenytoin 52-61 albumin Homo sapiens 96-103 2244404-5 1990 There was a significant negative correlation (r = -0.9, p less than 0.001) between the percentage of free phenytoin and the measured serum albumin. Phenytoin 106-115 albumin Homo sapiens 139-146 2244404-6 1990 In cancer patients, the serum albumin concentration appears to be the key factor that determines the percentage of free phenytoin. Phenytoin 120-129 albumin Homo sapiens 30-37 2244404-7 1990 In cancer patients with low serum albumin concentration, the total and free phenytoin concentration should be measured for adequate assessment of phenytoin therapy. Phenytoin 146-155 albumin Homo sapiens 34-41 25586596-6 2015 In this case report, an elderly female patient who experienced phenytoin toxicity was treated with albumin infusion, after which her phenytoin level returned to a therapeutic level with corresponding improvements in her symptoms. Phenytoin 63-72 albumin Homo sapiens 99-106 25586596-6 2015 In this case report, an elderly female patient who experienced phenytoin toxicity was treated with albumin infusion, after which her phenytoin level returned to a therapeutic level with corresponding improvements in her symptoms. Phenytoin 133-142 albumin Homo sapiens 99-106 3429058-11 1987 For practical purposes, the change in the free fractions of phenytoin and diazepam can be adequately predicted by the serum creatinine or urea and serum albumin levels. Phenytoin 60-69 albumin Homo sapiens 153-160 3674731-3 1987 The free fraction of phenytoin correlated negatively with the serum albumin concentration, and that of propranolol with the alpha 1-acid glycoprotein (alpha 1-AGP) concentration. Phenytoin 21-30 albumin Homo sapiens 68-75 3680582-0 1987 The relationship of serum albumin level to phenytoin toxicity. Phenytoin 43-52 albumin Homo sapiens 26-33 3674731-5 1987 In stepwise multiple regression analysis, the most significant variable for phenytoin free fraction was serum albumin concentration, with the serum urea concentration coming in second place. Phenytoin 76-85 albumin Homo sapiens 110-117 3674731-7 1987 When the effect of serum albumin level was corrected mathematically, the urea level was the best determinant in regression analysis for both the phenytoin and diazepam free fractions. Phenytoin 145-154 albumin Homo sapiens 25-32 421730-3 1979 At a serum concentration of 60 micromol.1-1 the percentage of phenytoin bound to serum albumin was considerably lower in the patient serum (79.95% predialysis; 92.09% postdialysis) than that in three normal sera (97.90 +/- 0.17%). Phenytoin 62-71 albumin Homo sapiens 81-94 7460484-0 1981 Phenytoin binding to partially purified albumin in renal disease. Phenytoin 0-9 albumin Homo sapiens 40-47 7460484-3 1981 Albumin, the primary binding protein for phenytoin (DPH), was isolated from the plasma of patients with severe renal failure as well as from normal controls. Phenytoin 41-50 albumin Homo sapiens 0-7 3950058-3 1986 For the drugs that bind predominantly to albumin, the serum free fractions were greater in patients one week after the burn incident than in control subjects (diazepam, 0.055 vs. 0.017; phenytoin, 0.24 vs. 0.16; and salicylic acid, 0.69 vs. 0.32). Phenytoin 186-195 albumin Homo sapiens 41-48 467465-3 1979 Palmitic acid and some acidic drugs, warfarin and phenylbutazone added to human serum albumin, decreased phenytoin binding in a non competitive way. Phenytoin 105-114 albumin Homo sapiens 80-93